AUS
NZ
UK
CA
USA
IND
Health
Short Interest Decline and Investor Moves in Fresenius Medical Care (NYSE:FMS)
December 31, 2024 08:55 AM PST| By Team Kalkine MediaHighlights,Short interest in Fresenius Medical Care decreased by 5.1% in December.,Hedge funds, including Wulff Hansen & Co., significantly raised their stakes in FMS.,The stock’s performance continues to show stability with a 50-day.,Fresenius Medic...
Emergent BioSolutions (NYSE:EBS) Stock Performance and Analyst Coverage
December 31, 2024 08:45 AM PST| By Team Kalkine MediaHighlights,Emergent BioSolutions now covered by HC Wainwright.,Institutional investors hold a strong 78.4% stake in Emergent BioSolutions.,The company maintains solid liquidity with a current ratio of 2.88.,Emergent BioSolutions has recently caught t...
Why Are Longeveron’s Quarterly Results Raising Eyebrows This Year?
December 31, 2024 12:26 AM PST| By Team Kalkine MediaHighlights,Longeveron,(NASDAQ:LGVN),operates in the biotechnology sector, focusing on regenerative medicine.,The company reported improved earnings compared to the same period last year.,Revenue figures exceeded expectations, reflecting growth in its...
Why Is Cellectis Struggling to Break Out of Its Slump?
December 31, 2024 12:18 AM PST| By Team Kalkine MediaHighlights,Cellectis focuses on gene editing solutions for advanced healthcare innovations.,The company operates within the biotechnology sector, developing precise gene therapies.,Cellectis has diverse applications for immunotherapy and genetic dise...
Analyzing Pfizer's (NYSE:PFE) Dividend Growth Amid Earnings Decline
December 30, 2024 07:29 AM PST| By Team Kalkine MediaHighlights,Pfizer increases dividend for the upcoming year to $0.43.,Dividend payout ratio expected to decrease but could still remain sustainable.,Concerns about long-term sustainability due to earnings volatility.,Pfizer Inc. a major player in the...
VolitionRx Ltd (NYSE:VNRX) A Leader in Epigenetic Blood Test Innovation
December 30, 2024 07:23 AM PST| By Team Kalkine MediaHighlights,VolitionRx focuses on epigenetics to aid in early cancer and disease detection.,Company’s market cap stands at $56.99 million with a P/E ratio of -1.71.,Institutional ownership and insider transactions highlight confidence in the company.,...
Why Is This AML Trial Raising Serious Questions About Current Treatments?
December 30, 2024 01:11 AM PST| By Team Kalkine MediaHighlights,Hemogenyx initiates clinical trial for HG-CT-1 in treating R/R AML.,Focus on evaluating safety and effects on survival and disease progression.,Conducted at a globally renowned cancer research institution.,Hemogenyx Pharmaceuticals PLC,(OT...
CEL-SCI (NYSE: CVM) Announces Public Offering to Support Multikine Development
December 30, 2024 12:06 AM PST| By Team Kalkine MediaHighlights,CEL-SCI plans to raise capital to fund continued development of Multikine cancer therapy.,ThinkEquity appointed as sole placement agent for the offering.,Offering subject to market conditions, with terms and size yet to be finalized.,CEL-S...
CVS Health Faces Challenges as Earnings Decline Weighs on Stock Performance
December 29, 2024 08:42 AM PST| By Team Kalkine MediaHeadlines,CVS Health's performance has seen significant challenges, with recent declines raising concerns.,The company's price-to-earnings ratio indicates market skepticism despite valuation appeal.,Investors are closely monitoring earnings trends fo...
The Impact of Market Volatility on Waters Corporation (NYSE:WAT)
December 27, 2024 05:13 AM PST| By Team Kalkine MediaHighlights,Impressive 17% price growth in recent months for Waters Corporation.,Fair valuation of the stock, priced 8.9% below its intrinsic value.,High beta indicates potential for exaggerated price movements in volatile markets.,Waters Corporation...
Viracta Therapeutics Explores Strategic Alternatives Amid Trial Closure
December 26, 2024 06:08 PM PST| By Team Kalkine MediaHighlights,Viracta Therapeutics announces it is exploring strategic alternatives, including mergers, licensing, or sales.,The company has decided to voluntarily close its NAVAL-1 Phase 2 clinical trial for Nana-val in EBV+ lymphomas to extend its cas...
Chemed’s (NYSE:CHE) Stock Hits a 52-Week Low Amid Financial Struggles
December 24, 2024 08:00 AM PST| By Team Kalkine MediaHighlights,Chemed’s stock hits a 52-week low of $517.44, down 1.1%.,Company missed analysts’ earnings expectations for the latest quarter.,Dividend payout maintained with a 0.39% yield, reflecting the company’s stability.,Chemed Corp recently hit a n...
Why Did Geode Capital Increase Holdings in Ligand Pharmaceuticals?
December 24, 2024 03:41 AM PST| By Team Kalkine MediaHighlights,Geode Capital increases its stake in Ligand Pharmaceuticals.,Ligand Pharmaceuticals operates in the biotechnology sector.,SEC filing reveals Geode Capital's updated holdings.,Ligand Pharmaceuticals,(NASDAQ:LGND),, a biotechnology company,...
Why Did NeoGenomics Surpass Market Projections This Quarter?
December 24, 2024 03:09 AM PST| By Team Kalkine MediaHighlights:,Quarterly revenue reached $167.8 million, showing growth.,EPS reported at $0.05, surpassing expectations.,Market capitalization stands at $2.12 billion.,NeoGenomics,(NASDAQ:NEO),operates within the medical research sector, focusing on pro...
Why Is Biogen Struggling to Maintain Stability in the Market?
December 24, 2024 02:26 AM PST| By Team Kalkine MediaHighlights,Market Cap stands at $21.77 billion for Biogen Inc.,52-week range between $145.07 and $268.30.,Current ratios: Quick ratio of 0.80 and current ratio of 1.26.,Biogen Inc.,(NASDAQ:BIIB),operates within the biotechnology sector, focusing on t...
AVITA Medical (NASDAQ: RCEL) Receives FDA Approval for RECELL GO Mini Cartridge for Smaller Wounds
December 23, 2024 11:04 PM PST| By Team Kalkine MediaHighlights,FDA approval for RECELL GO mini expands AVITA Medical's product portfolio.,New cartridge is optimized for treating smaller wounds, enhancing treatment flexibility.,Planned commercial rollout in Q1 2025 targets trauma and burn centers.,AVIT...
Principal Financial Group Expands Stake in Centene Co.
December 23, 2024 08:57 AM PST| By Team Kalkine MediaHeadlines,Principal Financial Group Inc. has expanded its ownership in Centene Co.,(NYSE:CNC),.,Institutional investors and hedge funds maintain significant ownership in Centene.,Centene's shares are witnessing diverse activity among institutional st...
Why Is MaxCyte Losing a Longstanding Board Member This Year?
December 23, 2024 02:43 AM PST| By Team Kalkine MediaHighlights,MaxCyte announces the retirement of Art Mandell from its Board.,Board member Mandell played a key role in company milestones.,Board to consist of nine directors post-retirement.,MaxCyte,(NASDAQ:MXCT),, a prominent company in the cell engin...
Why Is This Biotech Stock Making Headlines Before the Market Opens?
December 23, 2024 02:38 AM PST| By Team Kalkine MediaHighlights,Alvotech added to Nasdaq Biotechnology Index during annual reconstitution.,Inclusion based on market capitalization and daily trading volumes criteria.,Effective date coincides with U.S. market opening on December 23, 2024.,The biotechnolo...
Why Are Intra-Cellular Therapies Shares Struggling to Maintain Momentum?
December 23, 2024 01:59 AM PST| By Team Kalkine MediaHighlights,Intra-Cellular Therapies operates within the dynamic biopharmaceutical sector.,The company focuses on treatments addressing complex mental health conditions.,Recent stock performance reflects fluctuations common in the healthcare industry....
